Opere BioNTech BNTX

Vender
 Comprar

BioNTech gráfico en tiempo real

5m 15m 30m 1h 4h 1d 1w

Fundamentales del instrumento

Weekly Search
Weekly
Daily
Fecha Cerrar Cambio Cambio del % Apertura Alto Bajo

Últimas noticias

2025 Apr 05, 16:00

: Adelanto semanal: ¿Los datos de inflación de EE. UU. sorprenderán al mercado?

Forex Índices
2025 Mar 29, 16:00

Adelanto semanal: Llegan las nóminas no agrícolas de EE. UU.: Qué deberías esperar

2025 Mar 22, 16:00

Adelanto semanal: Inversores, atentos a la inflación y PCE para el movimiento de la Fed

Forex Índices
2025 Mar 15, 16:00

Adelanto semanal: BoJ, Fed, SNB y BoE: ¿Cómo afectarán al mercado?

2025 Mar 04, 16:00

Adelanto semanal: Inflación de EE. UU. y tasas del BoC serán el foco de atención

2025 Mar 01, 16:00

Adelanto semanal: El mercado espera la decisión de tasas del BCE y los datos laborales de EE. UU.

2025 Feb 22, 16:00

Adelanto semanal: Inflación en Australia e índice de precios PCE subyacente de EE. UU.

2025 Feb 13, 16:00

Adelanto semanal: ¿Realizarán el Banco de la Reserva de Australia y el Banco de la Reserva de Nueva Zelanda movimientos de tipos inesperados?

Información

Spread

1.1234

Spread (%)

1.2481 %

Apalancamiento

1:10

Interés a un día (Compra)

-0.0597 %

Interés a un día (Venta)

-0.0292 %

Divisa

USD

Horarios de los mercados

Market open

Miércoles

13:31 - 19:59

Lunes

13:31-19:59

Martes

13:31-19:59

Jueves

13:31-19:59

Viernes

13:31-19:59

Análisis y estadísticas

Apertura

---

Cierre anterior

---

Máximo/mínimo de 52 semanas

--- – ---

Capitalización de mercado

21129447424

Acciones en circulación

239971008

Fecha de ganancias (próxima)

0000-00-00

Rentabilidad por div.

2022-06-17

Fecha exdividendo

2022-06-02

Tasa de dividendo anual anticipado

0

Rendimiento de dividendo anual anticipado

0

GPA

-3.02

Conoce más sobre este instrumento

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Instrumentos relacionados

Activo
Vender
Comprar
Cambio del %

Opere ahora

Opere ahora

Opere ahora

Opere ahora
view_all_instruments
Trustpilot